, trials targeting reduction
in amputation within 1 year as a primary end point of
a revascularization strategy might be focused on the
subjects who overlap clinical class 4 and moderate/high
anticipated beneﬁt for revascularization.
The WIfI classiﬁcation system is not meant to function
as a stand-alone clinical decision-making tool. Patient risk
factors and comorbidities also play a major part in selecting
the best therapy. Existing proposed comorb